Stock Price Forecast

May 6, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Stereotaxis, Inc. chart...

About the Company

Stereotaxis Inc. is an American publicly traded corporation based in St. Louis MO, that makes robotic products to improve the clinical outcomes of electrophysiology studies. The most notable of Stereotaxis’ products is the NIOBE® ES Remote Magnetic Navigation (RMN) System. With the first iterations of the RMN system originally designed for applications within the brain, its current usage is guiding magnetic catheters during electrophysiology studies and catheter ablation procedures to treat arrhythmias in the heart. The technology has been approved by regulatory agencies in the United States, European Union and other countries around the world. Systems operate within cardiac catheter labs in hospitals and have been utilized in over 100,000 procedures worldwide as of 2017. In January 2022, Stereotaxis announced that the Fuwai Central China Cardiovascular Hospital has become the first in central China to establish a robotic electrophysiology program with the company's robotic magnetic navigation technology.

Exchange

NYSE

$26M

Total Revenue

182

Employees

$62M

Market Capitalization

-8.25

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $STXS News

Stereotaxis, Inc.

4mon ago, source: CNN

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary ...

Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation Catheter

11mon ago, source: Hosted on MSN

Stereotaxis Inc (NYSE: STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE: ABT) to integrate Abbott's EnSite X EP System with Stereotaxis ...

Stereotaxis Inc (STXS) Stock: A Look at the Analyst Recommendations

11d ago, source: newsheater

To put it simply, Stereotaxis Inc (STXS) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important ...

Stereotaxis (NYSEMKT: STXS)

4d ago, source: The Motley Fool

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary ...

Stereotaxis up, Boeing down in index of St. Louis-area publicly traded stocks

18d ago, source: The Business Journals

The top five performers year to date, with Brown’s analysis, are: Stereotaxis Inc. (NYSE: STXS) – up 49.14%. The company manufactures and designs systems to treat abnormal heart rhythms and ...

Stereotaxis, Inc. (STXS) Interactive Stock Chart - Yahoo Finance

3mon ago, source: Yahoo Finance

Stereotaxis, Inc. (AMEX:STXS) Q4 2023 Earnings Call Transcript March 4, 2024 Stereotaxis, Inc. reports earnings inline with expectations. Reported EPS is $-0.07 EPS, expectations were $-0.07. STXS isn ...

Stereotaxis Inc RJR1

5d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Stereotaxis, Inc. (STXS)

20d ago, source: Yahoo Finance

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that ...

Stereotaxis Inc. (RJR1.SG)

15d ago, source: Yahoo Finance

Stereotaxis, Inc. (AMEX:STXS) Q4 2023 Earnings Call Transcript March 4, 2024 Stereotaxis, Inc. reports earnings inline with expectations. Reported EPS is $-0.07 EPS, expectations were $-0.07.

Stereotaxis Inc.

22d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...